Barclays Maintains Overweight on Eli Lilly, Raises Price Target to $680
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Carter Gould has maintained an Overweight rating on Eli Lilly (NYSE:LLY) and increased the price target from $630 to $680.
January 23, 2024 | 1:16 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Barclays has reaffirmed its Overweight rating on Eli Lilly and raised the price target from $630 to $680, indicating a positive outlook on the stock.
The increase in price target by a major financial institution like Barclays typically suggests a strong conviction in the company's future performance and growth potential. This can often lead to increased investor confidence and a potential short-term rise in the stock price.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100